|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN Estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sitarz R, Skierucha M, Mielko J, Offerhaus
GJA, Maciejewski R and Polkowski WP: Gastric cancer: Epidemiology,
prevention, classification and treatment. Cancer Manag Res.
10:239–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takahashi T, Saikawa Y and Kitagawa Y:
Gastric cancer: Current status of diagnosis and treatment. Cancers
(Basel). 5:48–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sugano K: Screening of gastric cancer in
Asia. Best Pract Res Clin Gastroenterol. 29:895–905. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Japanese Gastric Cancer Association, .
Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric
Cancer. 20:1–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wagner AD, Syn NL, Moehler M, Grothe W,
Yong WP, Tai BC, Ho J and Unverzagt S: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev.
8:CD0040642017.PubMed/NCBI
|
|
7
|
Pan D: Hippo signaling in organ size
control. Genes Dev. 21:886–897. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Xu ZP, Yang YC, Zhu JS, Zhou Z
and Chen WX: Expression of yes-associated protein in gastric
adenocarcinoma and inhibitory effects of its knockdown on gastric
cancer cell proliferation and metastasis. Int J Immunopathol
Pharmacol. 25:583–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zanconato F and Piccolo S: Eradicating
tumor drug resistance at its YAP -biomechanical roots. EMBO J.
35:459–461. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou Y, Wang Y, Zhou W, Chen T, Wu Q,
Chutturghoon VK, Lin B, Geng L, Yang Z, Zhou L and Zheng S: YAP
promotes multi-drug resistance and inhibits autophagy-related cell
death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway.
Cancer Cell Int. 19:1792019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song J, Xie LX, Zhang XY, Hu P, Long MF,
Xiong F, Huang J and Ye XQ: Role of YAP in lung cancer resistance
to cisplatin. Oncol Lett. 16:3949–3954. 2018.PubMed/NCBI
|
|
13
|
Song R, Gu D, Zhang L, Zhang X, Yu B, Liu
B and Xie J: Functional significance of Hippo/YAP signaling for
drug resistance in colorectal cancer. Mol Carcinog. 57:1608–1615.
2018. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu T, Sun L and Zhu X: Yes-associated
protein enhances proliferation and attenuates sensitivity to
cisplatin in human gastric cancer cells. Biomed Pharmacother.
105:1269–1275. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi J, Li F, Yao X, Mou T, Xu Z, Han Z,
Chen S, Li W, Yu J, Qi X, et al: The HER4-YAP1 axis promotes
trastuzumab resistance in HER2-positive gastric cancer by inducing
epithelial and mesenchymal transition. Oncogene. 37:3022–3038.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu X, Xin Y, Xiao Y and Zhao J:
Overexpression of YAP1 is correlated with progression, metastasis
and poor prognosis in patients with gastric carcinoma. Pathol Oncol
Res. 20:805–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yue G, Sun X, Gimenez-Capitan A, Shen J,
Yu L, Teixido C, Guan W, Rosell R, Liu B and Wei J: TAZ is highly
expressed in gastric signet ring cell carcinoma. Biomed Res Int.
2014:3930642014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cruess AF, Zlateva G, Pleil AM and
Wirostko B: Photodynamic therapy with verteporfin in age-related
macular degeneration: A systematic review of efficacy, safety,
treatment modifications and pharmacoeconomic properties. Acta
Ophthalmol. 87:118–132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mae Y, Kanda T, Sugihara T, Takata T,
Kinoshita H, Sakaguchi T, Hasegawa T, Tarumoto R, Edano M, Kurumi
H, et al: Verteporfin-photodynamic therapy is effective on gastric
cancer cells. Mol Clin Oncol. 13:102020.PubMed/NCBI
|
|
20
|
Dasari VR, Mazack V, Feng W, Nash J, Carey
DJ and Gogoi R: Verteporfin exhibits YAP-independent
anti-proliferative and cytotoxic effects in endometrial cancer
cells. Oncotarget. 8:28628–28640. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Al-Moujahed A, Brodowska K, Stryjewski TP,
Efstathiou NE, Vasilikos I, Cichy J, Miller JW, Gragoudas E and
Vavvas DG: Verteporfin inhibits growth of human glioma in vitro
without light activation. Sci Rep. 7:76022017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dong L, Lin F, Wu W, Liu Y and Huang W:
Verteporfin inhibits YAP-induced bladder cancer cell growth and
invasion via Hippo signaling pathway. Int J Med Sci. 15:645–652.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH image to imageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huggett MT, Jermyn M, Gillams A, Illing R,
Mosse S, Novelli M, Kent E, Bown SG, Hasan T, Pogue BW and Pereira
SP: Phase I/II study of verteporfin photodynamic therapy in locally
advanced pancreatic cancer. Br J Cancer. 110:1698–1704. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brodowska K, Al-Moujahed A, Marmalidou A,
Meyer Zu Horste M, Cichy J, Miller JW, Gragoudas E and Vavvas DG:
The clinically used photosensitizer Verteporfin (VP) inhibits
YAP-TEAD and human retinoblastoma cell growth in vitro without
light activation. Exp Eye Res. 124:67–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Feng J, Gou J, Jia J, Yi T, Cui T and Li
Z: Verteporfin, a suppressor of YAP-TEAD complex, presents
promising antitumor properties on ovarian cancer. Onco Targets
Ther. 9:5371–5381. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo
W, Lu Y and Mills GB: Verteporfin inhibits YAP function through
up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J
Cancer Res. 6:27–37. 2015.PubMed/NCBI
|
|
29
|
Kang W, Tong JH, Chan AW, Lee TL, Lung RW,
Leung PP, So KK, Wu K, Fan D, Yu J, et al: Yes-associated protein 1
exhibits oncogenic property in gastric cancer and its nuclear
accumulation associates with poor prognosis. Clin Cancer Res.
17:2130–2139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li P, Sun D, Li X, He Y, Li W, Zhao J,
Wang Y, Wang H and Xin Y: Elevated expression of Nodal and YAP1 is
associated with poor prognosis of gastric adenocarcinoma. J Cancer
Res Clin Oncol. 142:1765–1773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hong SA, Son MW, Cho J, Jang SH, Lee HJ,
Lee JH, Cho HD, Oh MH and Lee MS: Low angiomotin-p130 with
concomitant high Yes-associated protein 1 expression is associated
with adverse prognosis of advanced gastric cancer. APMIS.
125:996–1006. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang S, Zhu L, Cao Y, Li L, Xie Y, Deng J
and Xiong J: Significant association of YAP1 and HSPC111 proteins
with poor prognosis in Chinese gastric cancer patients. Oncotarget.
8:80303–80314. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang L, Song X, Li X, Wu C and Jiang J:
Yes-Associated protein 1 as a novel prognostic biomarker for
gastrointestinal cancer: A meta-analysis. Biomed Res Int.
2018:40391732018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Choi W, Kim J, Park J, Lee DH, Hwang D,
Kim JH, Ashktorab H, Smoot D, Kim SY, Choi C, et al: YAP/TAZ
initiates gastric tumorigenesis via upregulation of MYC. Cancer
Res. 78:3306–3320. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morin-Kensicki EM, Boone BN, Howell M,
Stonebraker JR, Teed J, Alb JG, Magnuson TR, O'Neal W and Milgram
SL: Defects in yolk sac vasculogenesis, chorioallantoic fusion, and
embryonic axis elongation in mice with targeted disruption of
Yap65. Mol Cell Biol. 26:77–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tian Y, Kolb R, Hong JH, Carroll J, Li D,
You J, Bronson R, Yaffe MB, Zhou J and Benjamin T: TAZ promotes PC2
degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell
Biol. 27:6383–6395. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Plouffe SW, Lin KC, Moore JL III, Tan FE,
Ma S, Ye Z, Qiu Y, Ren B and Guan KL: The Hippo pathway effector
proteins YAP and TAZ have both distinct and overlapping functions
in the cell. J Biol Chem. 293:11230–11240. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hayashi H, Higashi T, Yokoyama N, Kaida T,
Sakamoto K, Fukushima Y, Ishimoto T, Kuroki H, Nitta H, Hashimoto
D, et al: An imbalance in TAZ and YAP expression in hepatocellular
carcinoma confers cancer stem cell-like behaviors contributing to
disease progression. Cancer Res. 75:4985–4997. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Finch-Edmondson ML, Strauss RP, Passman
AM, Sudol M, Yeoh GC and Callus BA: TAZ protein accumulation is
negatively regulated by YAP abundance in mammalian cells. J Biol
Chem. 290:27928–27938. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anti-cancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
42
|
Cerda-Opazo P, Valenzuela-Valderrama M,
Wichmann I, Rodríguez A, Contreras-Reyes D, Fernández EA,
Carrasco-Aviño G, Corvalán AH and Quest AFG: Inverse expression of
survivin and reprimo correlates with poor patient prognosis in
gastric cancer. Oncotarget. 9:12853–12867. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bertazza L, Mocellin S, Marchet A, Pilati
P, Gabrieli J, Scalerta R and Nitti D: Survivin gene levels in the
peripheral blood of patients with gastric cancer independently
predict survival. J Transl Med. 7:1112009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang J, Zhu Z, Sun Z, Sun X, Wang Z and
Xu H: Survivin gene expression increases gastric cancer cell
lymphatic metastasis by up-regulating vascular endothelial growth
factor-C expression levels. Mol Med Rep. 9:600–606. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Da C, Xin Y, Zhao J and Luo X:
Significance and relationship between Yes-associated protein and
survivin expression in gastric carcinoma and precancerous lesions.
World J Gastroenterol. 15:4055–4061. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang S, Zhang D and Sun B: Vasculogenic
mimicry: Current status and future prospects. Cancer Lett.
254:157–164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sun J, Sun B, Sun R, Zhu D, Zhao X, Zhang
Y, Dong X, Che N, Li J, Liu F, et al: HMGA2 promotes vasculogenic
mimicry and tumor aggressiveness by up-regulating Twist1 in gastric
carcinoma. Sci Rep. 7:22292017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bora-Singhal N, Nguyen J, Schaal C,
Perumal D, Singh S, Coppola D and Chellappan S: YAP1 regulates OCT4
activity and SOX2 expression to facilitate self-renewal and
vascular mimicry of stem-like cells. Stem Cells. 33:1705–1718.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong
J, Sun X and Li J: Verteporfin suppresses cell survival,
angiogenesis and vasculogenic mimicry of pancreatic ductal
adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci.
108:478–487. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim HS, Won YJ, Shim JH, Kim HJ, Kim J,
Hong HN and Kim BS: Morphological characteristics of vasculogenic
mimicry and its correlation with EphA2 expression in gastric
adenocarcinoma. Sci Rep. 9:34142019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kang MH, Jeong GS, Smoot DT, Ashktorab H,
Hwang CM, Kim BS, Kim HS and Park YY: Verteporfin inhibits gastric
cancer cell growth by suppressing adhesion molecule FAT1.
Oncotarget. 8:98887–98897. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Xiong J, Wang S, Chen T, Shu X, Mo X,
Chang G, Chen JJ, Li C, Luo H and Lee JD: Verteporfin blocks
Clusterin which is required for survival of gastric cancer stem
cell by modulating HSP90 function. Int J Biol Sci. 15:312–324.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Giraud J, Molina-Castro S, Seeneevassen L,
Sifré E, Izotte J, Tiffon C, Staedel C, Boeuf H, Fernandez S,
Barthelemy P, et al: Verteporfin targeting YAP1/TAZ-TEAD
transcriptional activity inhibits the tumorigenic properties of
gastric cancer stem cells. Int J Cancer. 146:2255–2267. 2020.
View Article : Google Scholar : PubMed/NCBI
|
